MCID: FLL027
MIFTS: 58

Fallopian Tube Carcinoma

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Carcinoma

MalaCards integrated aliases for Fallopian Tube Carcinoma:

Name: Fallopian Tube Carcinoma 12 52 14 69
Fallopian Tube Cancer 12 50 52 14
Cancer of the Fallopian Tube 12 50
Neoplasm of Fallopian Tube 12 29
Fallopian Tube Neoplasms 42 69
Malignant Neoplasm of Fallopian Tube 69
Malignant Neoplasm of Uterine Tube 12
Malignant Tumour of Fallopian Tube 12
Malignant Tumor of Fallopian Tubes 56
Malignant Tumor of Fallopian Tube 12
Tumor, Fallopian Tube, Malignant 12
Carcinoma of Fallopian Tube 12
Tumor of the Fallopian Tube 12
Cancer of Fallopian Tubes 56
Fallopian Tube Neoplasm 12
Malignant Tubal Tumor 56
Fallopian Tube Ca 12
Tubal Cancer 56

Characteristics:

Orphanet epidemiological data:

56
malignant tumor of fallopian tubes
Prevalence: 1-9/100000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:1963 DOID:1964
MeSH 42 D005185
ICD10 33 C57.0
ICD9CM 35 183.2
Orphanet 56 ORPHA180242
UMLS via Orphanet 70 C0153579 C0238122
ICD10 via Orphanet 34 C57.0

Summaries for Fallopian Tube Carcinoma

NIH Rare Diseases : 50 fallopian tube cancer develops in the tubes that connect a woman's ovaries and uterus. it is very rare and accounts for only 1-2% of all gynecologic cancers.  fallopian tube cancer occurs when normal cells in one or both tubes change and grow in an uncontrolled way, forming a mass called a tumor. cancer can begin in any of the different cell types that make up the fallopian tubes. the most common type is called adenocarcinoma (a cancer of cells from glands). leiomyosarcoma (a cancer of smooth muscle cells) and transitional cell carcinoma (a cancer of the cells lining the fallopian tubes) are more rare.  while some fallopian tube cancers actually begin in the tubes themselves, fallopian tube cancer is more often the result of cancer spreading from other parts of the body to the tubes. for example, the fallopian tubes are a common site of metastasis (spread) of cancers that started in the ovaries, uterus, endometrium, (the tissue lining the uterus) appendix, or colon.  women with fallopian tube cancer may experience symptoms, although some affected women may have no symptoms at all. the signs of fallopian tube cancer are often non-specific, meaning that they can also be signs of other medical conditions that are not cancer. signs and symptoms of fallopian tube cancer can include: irregular or heavy vaginal bleeding (especially after menopause); occasional abdominal or pelvic pain or feeling of pressure; vaginal discharge that may be clear, white, or tinged with blood; and a pelvic mass or lump. doctors use many tests to diagnose cancer of the fallopian tubes. some of these tests may include: pelvic examination, transvaginal ultrasound, a blood test that measures the tumor marker ca-125, computed tomography (ct or cat) scan, and magnetic resonance imaging (mri). fallopian tube cancer can be best treated when detected early. if the cancer has spread to the walls of the tubes or outside of the tubes, then there is a lower chance that the disease can be treated successfully. the stage of the cancer determines the type of treatment needed. most women will need surgery and some will go on to have chemotherapy and/or radiation therapy. last updated: 5/6/2015

MalaCards based summary : Fallopian Tube Carcinoma, also known as fallopian tube cancer, is related to endocervicitis and fallopian tube carcinosarcoma. An important gene associated with Fallopian Tube Carcinoma is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and GPCR Pathway. The drugs Olaparib and Poly(ADP-ribose) Polymerase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and testes, and related phenotypes are Synthetic lethal with cisplatin and behavior/neurological

Disease Ontology : 12 A female reproductive organ cancer that is located in fallopian tube.

Wikipedia : 72 Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates... more...

Related Diseases for Fallopian Tube Carcinoma

Diseases related to Fallopian Tube Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
id Related Disease Score Top Affiliating Genes
1 endocervicitis 29.5 BRCA1 BRCA2 ERBB2 TP53
2 fallopian tube carcinosarcoma 27.0 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
3 familiar fallopian tube carcinoma 12.0
4 fallopian tube adenocarcinoma 11.0
5 congenital disorder of glycosylation, type if 10.7 ERBB2 TP53
6 animal phobia 10.7 ERBB2 TP53
7 blastema predominant kidney wilms' tumor 10.7 PGR TP53
8 cystic kidney disease 10.7 ERBB2 TP53
9 gastritis 10.6 ERBB2 PGR
10 orbital lymphoma 10.6 ERBB2 TP53
11 breast myoepithelial neoplasm 10.6 PGR TP53
12 leiomyoma cutis 10.6 PGR TP53
13 prostatic acinar adenocarcinoma 10.6 PGR TP53
14 intraductal breast myoepitheliosis 10.6 PGR TP53
15 skin sarcoma 10.6 ERBB2 PGR
16 her2-receptor negative breast cancer 10.6 ERBB2 PGR
17 group b strep disease in newborns 10.6 ERBB2 TP53
18 thai symphalangism syndrome 10.6 BRCA2 TP53
19 central nervous system germ cell tumor 10.6 PGR TP53
20 kallmann syndrome 10.6 ERBB2 PGR
21 penis squamous cell carcinoma 10.6 ERBB2 PGR
22 primitive neuroectodermal tumor of the corpus uteri 10.6 BRCA1 BRCA2
23 baraitser-winter cerebrofrontofacial syndrome 10.5 BRCA1 BRCA2
24 bronchopulmonary dysplasia 10.5 BRCA1 BRCA2
25 extragonadal nonseminomatous germ cell tumor 10.5 PGR TP53
26 pancreatic cancer 4 10.5 BRCA1 BRCA2
27 cataract 27, nuclear progressive 10.5 BRCA1 BRCA2
28 bacteremia 10.5 BRCA1 BRCA2
29 eccrine sweat gland neoplasm 10.5 BRCA1 BRCA2
30 chronic frontal sinusitis 10.5 BRCA1 BRCA2
31 klatskin's tumor 10.5 ERBB2 PGR
32 ovarian endometrioid adenofibroma 10.4 BRCA1 BRCA2
33 pylorus cancer 10.4 TP53 VEGFA
34 fallopian tube clear cell adenocarcinoma 10.4 ESR1 TP53
35 diffuse lipomatosis 10.4 PGR VEGFA
36 mediastinum synovial sarcoma 10.4 BRCA1 BRCA2
37 sparse hair ptosis mental retardation 10.4 TP53 VEGFA
38 breast myoepitheliosis 10.4 ESR1 TP53
39 nerve fibre bundle defect 10.4 ERBB2 ESR1
40 bartholin's gland benign neoplasm 10.3 ESR1 PGR
41 gallbladder leiomyoma 10.3 ESR1 PGR
42 kidney benign neoplasm 10.3 ERBB2 PGR
43 fallopian tube benign neoplasm 10.3 ESR1 PGR
44 paranasal sinus disease 10.3 ESR1 PGR
45 dartoic leiomyoma 10.3 ESR1 PGR
46 colon neuroendocrine neoplasm 10.3 ERBB2 PGR TP53
47 breast fibrosarcoma 10.3 ERBB2 PGR TP53
48 urinary bladder inverted papilloma 10.3 ESR1 PGR
49 deafness, autosomal dominant 8/12 10.3 ESR1 PGR
50 rectum kaposi's sarcoma 10.3 ERBB2 PGR TP53

Comorbidity relations with Fallopian Tube Carcinoma via Phenotypic Disease Network (PDN):


Ovarian Cancer, Somatic

Graphical network of the top 20 diseases related to Fallopian Tube Carcinoma:



Diseases related to Fallopian Tube Carcinoma

Symptoms & Phenotypes for Fallopian Tube Carcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA2 BRCA1

MGI Mouse Phenotypes related to Fallopian Tube Carcinoma:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.19 BRCA1 ERBB2 BRCA2 MYC ESR1 PGR
2 cellular MP:0005384 10.18 BRCA1 ERBB2 BRCA2 MYC ESR1 PGR
3 embryo MP:0005380 10.16 BRCA1 ERBB2 BRCA2 ESR1 TP53 PGR
4 endocrine/exocrine gland MP:0005379 10.15 BRCA1 ERBB2 BRCA2 MYC ESR1 PGR
5 cardiovascular system MP:0005385 10.13 BRCA1 ERBB2 MYC ESR1 PGR VEGFA
6 homeostasis/metabolism MP:0005376 10.13 BRCA2 BRCA1 ERBB2 MYC ESR1 PGR
7 digestive/alimentary MP:0005381 10.11 BRCA1 ERBB2 BRCA2 MYC ESR1 VEGFA
8 integument MP:0010771 10.1 BRCA1 ERBB2 BRCA2 ESR1 TP53 PGR
9 hematopoietic system MP:0005397 10.08 BRCA2 BRCA1 MYC ESR1 PGR VEGFA
10 limbs/digits/tail MP:0005371 10.08 BRCA1 ERBB2 BRCA2 ESR1 TP53 PGR
11 mortality/aging MP:0010768 10.06 BRCA2 BRCA1 ERBB2 MYC ESR1 PGR
12 immune system MP:0005387 10.05 BRCA2 BRCA1 PGR MYC ESR1 VEGFA
13 neoplasm MP:0002006 10.01 ERBB2 BRCA2 ESR1 BRCA1 TP53 PGR
14 muscle MP:0005369 9.98 BRCA1 ERBB2 MYC ESR1 PGR VEGFA
15 nervous system MP:0003631 9.91 BRCA2 BRCA1 ERBB2 MYC ESR1 VEGFA
16 normal MP:0002873 9.86 BRCA1 ERBB2 BRCA2 ESR1 PGR MYC
17 reproductive system MP:0005389 9.76 BRCA1 ERBB2 BRCA2 ESR1 PGR MYC
18 no phenotypic analysis MP:0003012 9.72 PGR MYC ESR1 VEGFA TP53
19 respiratory system MP:0005388 9.35 BRCA1 ERBB2 ESR1 VEGFA TP53
20 skeleton MP:0005390 9.23 BRCA1 ERBB2 BRCA2 MYC ESR1 PGR

Drugs & Therapeutics for Fallopian Tube Carcinoma

Drugs for Fallopian Tube Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 349)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1 763113-22-0 23725625
2 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
7
Mechlorethamine Approved Phase 2, Phase 3 51-75-2 4033
8
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
11
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Epirubicin Approved Phase 3 56420-45-2 41867
14
Alvimopan Approved Phase 3 156053-89-3 5488548
15
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
18
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
19
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
21
Rucaparib Approved, Investigational Phase 3,Phase 2,Phase 1 283173-50-2 9931954
22
Armodafinil Approved, Investigational Phase 2, Phase 3 112111-43-0
23
Modafinil Approved, Investigational Phase 2, Phase 3 68693-11-8 4236
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
25
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
26
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
27
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
28
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1 56-86-0 33032
29
Dehydroepiandrosterone Approved, Nutraceutical Phase 3 53-43-0 9860744
30
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
31
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
32
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
33
Trebananib Investigational Phase 3,Phase 2,Phase 1 894356-79-7
34
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
35 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
36
Maleic acid Experimental Phase 3,Phase 2,Phase 1 110-16-7 444266
37
Fosbretabulin Investigational Phase 2, Phase 3 222030-63-9 5351387
38 Combretastatin Investigational Phase 2, Phase 3 82855-09-2
39 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
42 Alkylating Agents Phase 2, Phase 3, Phase 1
43 Isophosphamide mustard Phase 2, Phase 3
44 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
45 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
47 Antibodies Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49 Antimetabolites Phase 3,Phase 2,Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 583)

id Name Status NCT ID Phase Drugs
1 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
2 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
3 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
4 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
5 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
6 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
7 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
8 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
9 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
10 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
11 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
12 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
13 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
14 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
15 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
16 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
17 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
18 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
19 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
20 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
21 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
22 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
23 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
24 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
25 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
26 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
27 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
28 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
29 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
30 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
31 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
32 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
33 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
34 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
35 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
37 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Recruiting NCT02631876 Phase 3 IMGN853;Paclitaxel;Doxorubicin;Topotecan
38 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
39 Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23 Recruiting NCT02903004 Phase 3 Trabectedin;Pegylated Liposomal Doxorubicin;Topotecan;Gemcitabine;Weekly Paclitaxel;Carboplatin
40 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
41 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
42 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
43 A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. Recruiting NCT03106987 Phase 3 Active Comparator: Olaparib tablets;Placebo
44 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
45 Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) Recruiting NCT02718417 Phase 3 carboplatin;paclitaxel;Avelumab;Avelumab
46 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
47 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
48 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
49 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. Recruiting NCT02032823 Phase 3 Olaparib;Placebo
50 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex

Search NIH Clinical Center for Fallopian Tube Carcinoma

Cochrane evidence based reviews: fallopian tube neoplasms

Genetic Tests for Fallopian Tube Carcinoma

Genetic tests related to Fallopian Tube Carcinoma:

id Genetic test Affiliating Genes
1 Neoplasm of Fallopian Tube 29

Anatomical Context for Fallopian Tube Carcinoma

MalaCards organs/tissues related to Fallopian Tube Carcinoma:

39
Breast, Ovary, Testes, Colon, T Cells, Uterus, Appendix

Publications for Fallopian Tube Carcinoma

Articles related to Fallopian Tube Carcinoma:

(show all 49)
id Title Authors Year
1
Identifying features of primary fallopian tube carcinoma using magnetic resonance imaging. ( 28721103 )
2017
2
Skin metastases in epithelial ovarian and fallopian tube carcinoma. ( 28816970 )
2017
3
Evaluation of Short-Term Efficacy of Concurrent Chemoradiotherapy in Primary Fallopian Tube Carcinoma by Diffusion-Weighted Imaging: A Retrospective Study. ( 28423375 )
2017
4
Primary Fallopian Tube Carcinoma: A Case Report and Literature Review. ( 28698755 )
2017
5
Triple Synchronous Malignancies in Genital Tract; Primary Endometrial, Ovarian and Fallopian Tube Carcinoma: A Case Report. ( 28274004 )
2017
6
Associations of Promoter Methylations and mRNA Expressions of MMP-2, MMP-7 and MMP-9 with Primary Fallopian Tube Carcinoma. ( 26785083 )
2016
7
Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 26712194 )
2016
8
Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. ( 27307153 )
2016
9
Response to comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122290 )
2016
10
Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study. ( 26825825 )
2016
11
Comment on Shama Chaudhry et al (J Pak Med Assoc 2016; 66: 107-110) Rare primary fallopian tube carcinoma; a gynaecologist's dilemma. ( 27122289 )
2016
12
Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery. ( 27976970 )
2016
13
Robotic resection of bulky aorto-caval lymphadenopathy in a patient with serous fallopian tube carcinoma. ( 25449567 )
2015
14
Prognostic Significance of Retroperitoneal Lymphadenectomy, Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Primary Fallopian Tube Carcinoma: A Multicenter Study. ( 25622588 )
2015
15
Primary fallopian tube carcinoma--a retrospective analysis of 66 cases. ( 26050354 )
2015
16
Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma. ( 25846583 )
2015
17
Clinically Occult Primary Fallopian Tube Carcinoma Presenting as a Malignant Pleural Effusion. ( 26646473 )
2015
18
Metastatic fallopian tube carcinoma presenting as an inguinal hernia. ( 25675933 )
2015
19
Primary fallopian tube carcinoma: review of MR imaging findings. ( 26150249 )
2015
20
Magnetic resonance imaging features of fallopian tube carcinoma. ( 25890392 )
2015
21
Primary fallopian tube carcinoma: correlation between magnetic resonance and diffuse weighted imaging characteristics and histopathologic findings. ( 25373473 )
2015
22
Primary fallopian tube carcinoma diagnosed preoperatively by cervical smear. ( 25827704 )
2014
23
Primary fallopian tube carcinoma diagnosed with endoscopic ultrasound elastography with fine needle biopsy. ( 25325010 )
2014
24
Genomic aberrations of BRCA1-mutated fallopian tube carcinomas. ( 24726640 )
2014
25
Primary fallopian tube carcinoma: a case report and mini-review of the literature. ( 25507436 )
2014
26
Clinical and survival analysis of 36 cases of primary fallopian tube carcinoma. ( 25307473 )
2014
27
Primary fallopian tube carcinoma: a case report and mini-review of the literature. ( 25423713 )
2014
28
Primary fallopian tube carcinoma: a case report. ( 25426210 )
2014
29
Co-existence of primary fallopian tube carcinoma and uterine carcinosarcoma. ( 24912001 )
2014
30
Primary fallopian tube carcinoma and ectopic pregnancy: A rare co-occurrence. ( 24411050 )
2013
31
Uncommon manifestations of Endocervical Malignant Mixed Mullerian Tumor with Incidental Bilateral Fallopian Tube Carcinoma. ( 21701666 )
2011
32
Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features. ( 22038216 )
2011
33
Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. ( 19761129 )
2009
34
Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. ( 19898224 )
2009
35
Expression of insulin-like growth factor-1 receptors, Wilm's tumor-1 protein, c-kit and p16 in primary fallopian tube carcinoma in diabetic patients. ( 17972088 )
2008
36
Microinvasive fimbrial fallopian tube carcinoma in a BRCA-2 mutation carrier. ( 18207147 )
2008
37
HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. ( 17927588 )
2007
38
Fallopian tube carcinoma: incidental finding during surgery for acute pelvic inflammatory disease--case report. ( 17139993 )
2006
39
Management of bilateral fallopian tube carcinoma coexistent with tuberculous salpingitis. ( 15669995 )
2005
40
BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? ( 16319259 )
2005
41
Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. ( 15252324 )
2004
42
Tuberculous salpingitis in two of five primary fallopian tube carcinomas. ( 12745571 )
2003
43
Incidental diagnosis of primary fallopian tube carcinoma during prophylactic salpingo-oophorectomy in BRCA2 mutation carrier. ( 12504983 )
2002
44
Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. ( 10785486 )
2000
45
Recurrent fallopian tube carcinoma: TP53 mutation and clinical course. ( 10782411 )
2000
46
Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. ( 10629373 )
2000
47
c-erbB-2 and p53 expression in fallopian tube carcinoma. ( 7773939 )
1995
48
Primary fallopian tube carcinoma with coexistent tuberculous salpingitis: a case report. ( 1556508 )
1992
49
Exfoliative dermatitis: presenting sign of fallopian tube carcinoma. ( 2967452 )
1988

Variations for Fallopian Tube Carcinoma

Cosmic variations for Fallopian Tube Carcinoma:

9 (show top 50) (show all 94)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM6932 TP53 endometrium,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 6
2 COSM10648 TP53 endometrium,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 6
3 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 6
4 COSM10656 TP53 endometrium,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 6
5 COSM43596 TP53 endometrium,NS,carcinoma,adenocarcinoma c.841G>A p.D281N 6
6 COSM10659 TP53 endometrium,NS,carcinoma,adenocarcinoma c.817C>T p.R273C 6
7 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 6
8 COSM10709 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 6
9 COSM44063 TP53 endometrium,NS,carcinoma,adenocarcinoma c.389T>G p.L130R 6
10 COSM10704 TP53 endometrium,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 6
11 COSM11073 TP53 endometrium,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 6
12 COSM44622 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 6
13 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 6
14 COSM10654 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 6
15 COSM45035 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 6
16 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 6
17 COSM43545 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 6
18 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 6
19 COSM10863 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.833C>T p.P278L 6
20 COSM43955 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.514G>A p.V172I 6
21 COSM10794 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.796G>A p.G266R 6
22 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 6
23 COSM14050 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1516G>A p.V506M 6
24 COSM14049 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1067C>T p.P356L 6
25 COSM5154 PTEN endometrium,NS,carcinoma,adenocarcinoma c.697C>T p.R233* 6
26 COSM5107 PTEN endometrium,NS,carcinoma,adenocarcinoma c.71A>G p.D24G 6
27 COSM5216 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>T p.R130L 6
28 COSM5235 PTEN endometrium,NS,carcinoma,adenocarcinoma c.218A>T p.E73V 6
29 COSM5299 PTEN endometrium,NS,carcinoma,adenocarcinoma c.271G>T p.E91* 6
30 COSM5152 PTEN endometrium,NS,carcinoma,adenocarcinoma c.388C>T p.R130* 6
31 COSM5236 PTEN endometrium,NS,carcinoma,adenocarcinoma c.275A>T p.D92V 6
32 COSM5219 PTEN endometrium,NS,carcinoma,adenocarcinoma c.388C>G p.R130G 6
33 COSM5312 PTEN endometrium,NS,carcinoma,adenocarcinoma c.895G>T p.E299* 6
34 COSM5106 PTEN endometrium,NS,carcinoma,adenocarcinoma c.335T>C p.L112P 6
35 COSM5065 PTEN endometrium,NS,carcinoma,adenocarcinoma c.403A>G p.I135V 6
36 COSM5039 PTEN endometrium,NS,carcinoma,adenocarcinoma c.518G>A p.R173H 6
37 COSM5048 PTEN endometrium,NS,carcinoma,adenocarcinoma c.196A>G p.K66E 6
38 COSM5159 PTEN endometrium,NS,carcinoma,adenocarcinoma c.733C>T p.Q245* 6
39 COSM5115 PTEN endometrium,NS,carcinoma,adenocarcinoma c.155A>G p.D52G 6
40 COSM5033 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>A p.R130Q 6
41 COSM5943 PTEN endometrium,NS,carcinoma,adenocarcinoma c.634+3A>C p.? 6
42 COSM5276 PTEN endometrium,NS,carcinoma,adenocarcinoma c.386G>T p.G129V 6
43 COSM5105 PTEN endometrium,NS,carcinoma,adenocarcinoma c.284C>T p.P95L 6
44 COSM5212 PTEN endometrium,NS,carcinoma,adenocarcinoma c.319G>T p.D107Y 6
45 COSM5108 PTEN endometrium,NS,carcinoma,adenocarcinoma c.209T>C p.L70P 6
46 COSM5165 PTEN endometrium,NS,carcinoma,adenocarcinoma c.519C>T p.R173R 6
47 COSM5215 PTEN endometrium,NS,carcinoma,adenocarcinoma c.356T>A p.V119D 6
48 COSM937333 POLE endometrium,NS,carcinoma,adenocarcinoma c.857C>G p.P286R 6
49 COSM5031089 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>A p.S297Y 6
50 COSM937331 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>T p.S297F 6

Expression for Fallopian Tube Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Carcinoma.

Pathways for Fallopian Tube Carcinoma

Pathways related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 49)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 BRCA1 ERBB2 ESR1 MYC PGR PSMB4
2
Show member pathways
13.52 BRCA1 BRCA2 ERBB2 ESR1 MYC TP53
3
Show member pathways
13.35 BRCA1 ERBB2 MYC PSMB4 TP53 VEGFA
4
Show member pathways
13.18 ERBB2 MYC PSMB4 TP53 VEGFA
5
Show member pathways
12.68 BRCA1 ESR1 MYC PSMB4 TP53
6
Show member pathways
12.64 ERBB2 ESR1 TP53 VEGFA
7 12.53 BRCA1 MYC TP53 VEGFA
8 12.47 BRCA2 ERBB2 MYC TP53 VEGFA
9 12.33 BRCA1 ERBB2 MYC TP53 VEGFA
10
Show member pathways
12.27 BRCA1 ESR1 VEGFA
11
Show member pathways
12.24 BRCA1 MYC TP53
12
Show member pathways
12.24 BRCA1 BRCA2 ESR1 MYC PSMB4 TP53
13
Show member pathways
12.17 ERBB2 MYC TP53
14
Show member pathways
12.12 BRCA1 PSMB4 TP53
15
Show member pathways
12.07 BRCA1 ESR1 MYC PGR
16 12.04 MYC TP53 VEGFA
17 12.03 ERBB2 ESR1 MYC TP53 VEGFA
18 11.92 PSMB4 TP53 VEGFA
19
Show member pathways
11.91 BRCA1 BRCA2 ERBB2 ESR1 MYC PGR
20 11.87 ESR1 MYC TP53
21 11.86 ERBB2 MYC TP53
22 11.86 MYC TP53 VEGFA
23
Show member pathways
11.83 ERBB2 ESR1 PGR
24
Show member pathways
11.71 BRCA1 BRCA2 TP53
25
Show member pathways
11.7 ERBB2 ESR1 MYC VEGFA
26 11.64 BRCA1 ERBB2 TP53
27 11.58 ERBB2 MYC TP53
28 11.57 ERBB2 MYC TP53 VEGFA
29 11.55 BRCA1 ERBB2 MYC
30 11.49 BRCA1 ERBB2 MYC TP53
31 11.43 ESR1 MYC VEGFA
32 11.4 BRCA1 MYC TP53
33 11.37 BRCA1 MYC TP53
34 11.34 ESR1 MYC TP53
35 11.29 BRCA1 BRCA2 ESR1 MYC TP53 VEGFA
36 11.27 ESR1 TP53
37 11.27 TP53 VEGFA
38 11.27 BRCA1 MYC TP53 VEGFA
39 11.25 BRCA2 ESR1 MYC
40 11.24 ESR1 TP53
41 11.21 MYC TP53
42 11.19 BRCA1 TP53
43 11.18 BRCA1 TP53
44 11.14 BRCA1 TP53
45 11.12 ESR1 MYC
46 11.12 MYC TP53
47 11 MYC TP53
48
Show member pathways
11 MYC TP53
49 10.93 BRCA1 TP53

GO Terms for Fallopian Tube Carcinoma

Cellular components related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.5 BRCA1 BRCA2 ESR1 MYC PGR PSMB4
2 nuclear chromatin GO:0000790 9.26 ESR1 TP53
3 lateral element GO:0000800 9.16 BRCA1 BRCA2
4 protein complex GO:0043234 9.02 BRCA1 BRCA2 ESR1 MYC TP53

Biological processes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.83 BRCA1 BRCA2 ESR1 MYC TP53
2 cellular response to DNA damage stimulus GO:0006974 9.8 BRCA1 BRCA2 MYC TP53
3 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.8 BRCA1 ESR1 MYC PGR TP53 VEGFA
4 regulation of transcription from RNA polymerase II promoter GO:0006357 9.77 BRCA1 ERBB2 ESR1 MYC VEGFA
5 cellular response to hypoxia GO:0071456 9.65 MYC TP53 VEGFA
6 positive regulation of epithelial cell proliferation GO:0050679 9.63 ERBB2 MYC VEGFA
7 DNA synthesis involved in DNA repair GO:0000731 9.61 BRCA1 BRCA2
8 negative regulation of fibroblast proliferation GO:0048147 9.59 MYC TP53
9 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.58 BRCA2 TP53
10 cell aging GO:0007569 9.58 BRCA2 TP53
11 chromosome organization GO:0051276 9.57 BRCA2 MYC
12 positive regulation of mesenchymal cell proliferation GO:0002053 9.56 MYC VEGFA
13 positive regulation of cell cycle arrest GO:0071158 9.55 BRCA1 TP53
14 positive regulation of gene expression GO:0010628 9.55 BRCA1 ERBB2 MYC TP53 VEGFA
15 strand displacement GO:0000732 9.54 BRCA1 BRCA2
16 response to X-ray GO:0010165 9.52 BRCA2 TP53
17 mammary gland alveolus development GO:0060749 9.51 ESR1 VEGFA
18 response to gamma radiation GO:0010332 9.43 BRCA2 MYC TP53
19 chordate embryonic development GO:0043009 9.4 BRCA1 BRCA2
20 protein deubiquitination GO:0016579 9.35 BRCA1 ESR1 MYC PSMB4 TP53
21 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53
22 transcription, DNA-templated GO:0006351 10.08 BRCA1 ERBB2 ESR1 MYC PGR TP53

Molecular functions related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.43 BRCA1 BRCA2 ESR1 MYC PGR TP53
2 steroid binding GO:0005496 9.16 ESR1 PGR
3 enzyme binding GO:0019899 8.92 BRCA1 ESR1 PGR TP53

Sources for Fallopian Tube Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....